• Research Tree
  • Features
  • Pricing
  • Events
  • Reg.News
  • Short Interest
  • Explore Content
    • Explore

      • Providers
        • Providers

          • Free/Commissioned
          • High Net Worth Offering
          • Institutional Offering

          Free/Commissioned

          Research that is free to access for all investors. Companies commission these providers to write research about them.

          View Research

          What is our Main Bundle Offering?

          Brokers who write research on their corporate clients and make it available through our main bundle offering.

          View Research

          What is Institutional?

          Research that is paid for directly by asset managers. Only accessible to institutional investors permissioned for access.

          View Research
      • Regions
        • Regions

          • UK
          • Rest of EMEA
          • N America
          • APAC
          • LatAm
      • Exchanges
        • Exchanges

          • Aquis Apex
          • Australian Securities Exchange
          • Canadian Securities Exchange
          • Euronext Paris
          • London Stock Exchange (domestic)
          • SIX Swiss Exchange
      • Sectors
        • Sector Coverage

          • Building & Construction
          • Discretionary Personal Goods
          • Discretionary Retail
          • Energy
          • Health
          • Investment Trusts
          • Media
          • Resources
          • Technology
      • Small / Large Cap
        • Small / Large Cap

          • UK100
          • UK250
          • UK Smallcap
          • UK Other Main Markets
          • Other
  • Login
  • Sign Up
LIVE

Event in Progress:

Join Here ×
Research on related companies


Related Content

View the latest research on other companies in the sector. 

New COVID-19 workplace testing service

When in doubt about pandemics, ask an expert. One of the best being former FDA Commissioner Dr Scott Gottlieb (non-exec director of Pfizer & Illumina), who has been calling for widespread COVID-19 workplace testing for some time. Today came news that there is now one such test available for all American businesses, freelancers, ‘gig’ workers &/or sole traders. This new tech-enabled solution is powered by CLSU’s ClearContact, ClearID and Virtual Badge (strategic partnership) applications, in conjunction with Clinical Reference Laboratory’s (CRL) expertise in blood/antibody & saliva tests.

CLEARSTAR

  • 21 May 20
  • -
  • Equity Development
H2 demand surge anticipated as US reopens

Thankfully pandemics don’t come around very often. The last one of such virulence as COVID-19 being the ‘Spanish Flu’ in 1918-20. So how is ClearStar faring? Today’s 2019 results (see below) were in line with our revised expectations - reporting adjusted EBITDA (post SBPs) of $370k (-$108k LY) on turnover up 14.1% LFL to £23.0m ($20.1m). Driven by strong top line growth from Medical (+21.4%, MIS) & Direct (+31.9%), together climbing 26.2% to $16.5m (71.8% of group). Albeit partly offset by an 8.3% contraction at channel partners (non MIS), which reduced gross margins to 54.1% vs 56.4% LY, reflecting adverse divisional mix.

CLEARSTAR

  • 06 May 20
  • -
  • Equity Development
Deeply undervalued, high growth stock

It’s been a ‘FTSE slug fest’ over the past 3 months. Firstly investors were rattled by US/China trade tensions, then uncertainty about Brexit/General Election, and more recently by conflict in Iran/Iraq and the deadly Coronavirus. The latter sending Chinese equities, travel stocks, crude oil, commodities and many other assets plummeting.

CLEARSTAR

  • 10 Feb 20
  • -
  • Equity Development
Brief lull in financial screening volumes

Underlying demand for ClearStar’s tech-rich background & medical (MIS) screening services remains buoyant, as evidenced by its record orderbook and healthy pipeline – augmented by November’s ebullient US jobs report, where unemployment fell to a 50- year low of 3.5%

CLEARSTAR

  • 17 Dec 19
  • -
  • Equity Development
Clinically proven to deliver faster growth

Recruiting skilled, trustworthy and committed staff is a tricky & often cumbersome process, especially in today’s tight US labour market (3.7% unemployment). Get it wrong, and capable candidates go to rivals. Equally hiring poor employees can damage an organisation’s results, brand & culture. No more so than in the regulated areas of healthcare, transport, petro-chemicals, defence, logistics, education and financial services.

CLEARSTAR

  • 18 Sep 19
  • Equity Development
Another blockbuster month in July

If you’re concerned about Brexit, Sterling’s devaluation, currency wars and/or the slowing global economy, then look no further than Uncle’s Sam’s backyard. To us, America remains the ‘destination of choice’ for many investors, given its resilient consumer (>70% GDP), low unemployment (3.7%), solid GDP (2.1% Q2’19) and muted inflation (CPI 2.1%). The only problem is finding the right companies to buy at attractive levels. Step forward ClearStar, a tech-enabled background & medical (MIS) screening expert, based in Atlanta (Georgia), serving almost exclusively the US domestic market (c. 95% sales).

CLEARSTAR

  • 08 Aug 19
  • Equity Development
Organic growth is accelerating, and quickly

There are few principles in life that work consistently through ‘thick and thin’. One of the most important (& usually hardest to find) for investors is purchasing ‘quality growth stocks at attractive prices’. Enter ClearStar, who this morning (ahead of its AGM) said that LFL sales had climbed 14% in the first 5 months of 2019.

CLEARSTAR

  • 18 Jun 19
  • -
  • Equity Development
How to buy $1 bills for less than 25 cents

Tech firms are often faced with trade-offs. Take Amazon, who for years prioritised growth ahead of profitability in order to build dominant positions in online retail, cloud services and voice-search (re Alexa/Echo). Likewise, we think ClearStar is adopting a similar long term strategy to create shareholder value. Sure if it decided to switch off the ‘expansion button’ today, then earnings would immediately flow through. However, what we’re talking about here is a much bigger opportunity – disrupting an addressable market worth c. $4bn pa.

CLEARSTAR

  • 13 May 19
  • -
  • Equity Development
Happy customers beget happy investors

World class companies have one thing in common. They are all totally committed about delighting their customers. Knowing that this can create a powerful feedback loop, and likewise trigger more client wins, higher hit rates, positive referrals and follow-on work. Today we saw this virtuous circle in action again at ClearStar, a specialist in background & medical screening solutions. Announcing that it had secured a new 3 month $350,000 contract. Both extending and expanding the services it already provides to a relatively new professional services client within the financial services space.

CLEARSTAR

  • 29 Apr 19
  • -
  • Equity Development
Double digit growth continues into Q1’19

Long term value creation is all about customer focus, profitable growth and 1 st class execution. Concentrating on what clients want today and in the future - and doing it better than anyone else. We think that Clearstar, a technology-rich background employment and medical (MIS) screening provider, has this in spades. Saying this morning, that its strong growth in 2018 (+13% to $20.1m) had continued into Q1’19 - posting record turnover, up 11% LFL to $5.1m ($4.6m LY).

CLEARSTAR

  • 10 Apr 19
  • -
  • Equity Development
‘Disruptive’ US tech firm set for banner 2019

Many day traders think they know better than the market, yet get royally ‘tumbledryered’ whenever the FTSE goes into ‘psychosis mode’. For long-term value investors though, volatility means ‘opportunity’.

CLEARSTAR

  • 23 Jan 19
  • -
  • Equity Development
2 new contracts totalling >$1m of revenues

10 years on from the $600bn Lehman Bros bankruptcy and subsequent financial crisis, regulators have been busily cleaning up the industry in order to prevent it from ever happening again. Tougher laws have been introduced, fraudulent employees imprisoned and new staff probity checks introduced. Indeed, only last Friday the UK Government announced it had deported Kweku Adoboli, a former UBS trader who was convicted of a £1.4bn fraud between 2008–11.

CLEARSTAR

  • 20 Nov 18
  • -
  • Equity Development
Exciting new channel partner

Often the best ideas are the simplest. Take the humble employee ID and/or visitor card. There are probably 10s if not 100s of millions of these dished out globally each year to new recruits, temporary workers, contractors, visitors, etc. Not only costing a small fortune to produce, but also needlessly sucking in vital resource, slowing up the onboarding process and damaging the environmental (re plastic).

CLEARSTAR

  • 16 Oct 18
  • -
  • Equity Development
Valuation raised due to accelerating growth

Occasionally analysts can be guilty of over complicating matters. Strip out the jargon however, and often even the most complex of businesses can be distilled into four simple questions. Are revenues growing faster than costs? Will this be maintained in the long run? Is management investing enough to stay ahead of the game? And finally, how much are the shares worth compared to the current price? For ClearStar - a tech-pioneer in the $4bn global job screening (60% H1 sales) and medical (MIS 40%) testing market - we unequivocally got the thumbs-up again from this morning’s very encouraging H1’18 results.

CLEARSTAR

  • 17 Sep 18
  • -
  • Equity Development
Record revenues and positive EBITDA

UK investors are in a dilemma. BREXIT concerns, trade tensions and fears over another general election are all weighing on business confidence and pressurising the £. So where’s a good place to put one’s money? For myself, I’ve followed the advice of famous author & newspaper editor Horace Greeley to “go West, young man”. Allocating a sizable chunk of my own funds to America.

CLEARSTAR

  • 18 Jul 18
  • -
  • Equity Development
Broadening of medical testing service

The momentum at ClearStar seems to be building. At the 22nd May trading update, CLSU announced that it had secured new work with the likes of Gulfstream Aerospace, Hilmar Cheese and BNSF Railway Company (a Berkshire Hathaway company).

CLEARSTAR

  • 20 Jun 18
  • -
  • Equity Development
Valuation rises to 95p/share

How do you decide which equities to buy? Many people rely on the ‘comfort of the crowd’. Preferring to follow what others do to steer them through the markets. Like passive index trackers, this is fine up to a point, say when investing in highly liquid FTSE100 companies. But what about microcaps, where daily trading volumes can be much thinner, and the ‘crowd’ may not exist? Here instead, active fund managers typically focus on the fundamentals and back their own judgement to guide decision-making.

CLEARSTAR

  • 22 May 18
  • -
  • Equity Development
Quality stock at a rock-bottom price

Warren Buffett, the ‘Sage of Omaha’, has spoken many wise words during his accomplished career. Not least that “markets can stay irrational for far longer” than one might expect - yet ultimately they’re “weighing machines”, so value wins out in the end.

CLEARSTAR

  • 17 Apr 18
  • -
  • Equity Development
Medical and direct sales powering growth

Despite the unwelcome impact of Hurricanes Harvey and Irma in its backyard states of Florida, Georgia, South Carolina and Texas, ClearStar nonetheless reported impressive 2017 trading yesterday. Bang in line with our pre-storm estimates (from July), with revenues up 11% LFL (split 12% H1: 10% H2) to $17.8m (vs $16.0m LY) and net cash closing December at $1m (vs $1.5m June and $2.25m LY). Growth being driven by buoyant demand for direct screening (+21%) and medical/drug testing (+20%) services. The latter now (including channel partners) accounting for 38% (35% LY) of revenues, with the former equally set to climb from 24% in 2016 to >50% by 2024.

CLEARSTAR

  • 11 Jan 18
  • -
  • Equity Development
12% LFL growth driving record H1 sales

Trying to guess where the FTSE will be in 6-12 months is a bit of a crapshoot. Not so for ClearStar, where circa 90% of turnover relates to ‘repeat’ everyday background/employment and drug/alcohol screening tests (run-rate >8m pa). Better still, retention is an impressive 90% - which when added to the natural flow through of recently signed deals, the ‘on-boarding’ of existing clients, and today’s ‘bang in line’ interims – means there is >95% and >85% respectively of revenue cover for this year ($17.8m) and next ($19.8m).

CLEARSTAR

  • 19 Sep 17
  • -
  • Equity Development
Booming ‘gig’ economy driving growth

Don’t you just love ‘Tech’? Churning out irresistible growth rates, profit margins and cashflows, allied to robust visibility and high client retention. A compelling mix. The only problem is that many others do as well, pushing valuations to often nose-bleed levels.

CLEARSTAR

  • 12 Jul 17
  • -
  • Equity Development
Check this out

ClearStar is a well established tech platform and service provider to the background check industry with circa 2,300 generally very sticky customers. In fact ClearStar now serves over 27,000 employees annually and has over a 90% retention rate. The company is vying for profitability through both the execution of a targetted growth strategy and the search for further internal efficiencies. During 2016 the company expects to recognise circa $1.2m of annualised cost savings.

CLEARSTAR

  • 05 Nov 15
  • -
  • Hybridan
Research Tree
Useful Links
  • Features
  • Pricing
  • RNS/Newswires Feeds
  • Providers Hub
  • Company Hub
  • Stock Pick League
  • Chrome Extension
  • iOS and Android Apps
Account
  • Login
  • Join Now
  • Contact
  • Follow us on Linkedin
  • Follow us on X

© Research Tree 2025

  • Apple Store
  • Play Store
  • Terms of Service
  • Privacy Policy and Statement on Cookies

Research Tree will never share your details with third parties for marketing purposes. Research Tree distributes research documents that have been produced and approved by Financial Conduct Authority (FCA) Authorised & Regulated firms as well as relevant content from non-authorised sources, who are not regulated but the information is in the public domain. For the avoidance of doubt Research Tree is not giving advice, nor has Research Tree validated any of the information.

Research Tree is an Appointed Representative of Sturgeon Ventures which is Authorised and Regulated by the Financial Conduct Authority.

Top
  • Home
  • Features
  • Pricing
  • Event Hub
  • Reg.News
  • Short Interest Tracker
  • Explore Content
    • Regions
      • UK
      • Rest of EMEA
      • N America
      • APAC
      • LatAm
    • Exchanges
      • Aquis Apex
      • Australian Securities Exchange
      • Canadian Securities Exchange
      • Euronext Paris
      • London Stock Exchange (domestic)
      • SIX Swiss Exchange
    • Sectors
      • Automobile Industry
      • Banks
      • Building & Construction
      • Chemicals
      • Discretionary Personal Goods
      • Discretionary Retail
      • Energy
      • ETFs
      • Financial Services
      • Food & Drink
      • Food Production
      • Health
      • Household Goods & DIY
      • Industrial Equipment, Goods & Services
      • Insurance & Reinsurance
      • Investment Trusts
      • Leisure, Tourism & Travel
      • Media
      • Open-ended Funds
      • Other
      • Real Estate
      • Resources
      • Staple Retail
      • Technology
      • Telecoms
      • Utilities
    • Small / Large Cap
      • UK100
      • UK250
      • UK Smallcap
      • UK Other Main Markets
      • Other
    • Private/EIS
      • EIS Single Company
      • EIS/SEIS Funds
      • IHT Products
      • SEIS Single Company
      • VCT Funds
  • Providers
    • Free/Commissioned
      • Acquisdata
      • Actinver
      • Actio Advisors
      • Asset TV
      • Astris Advisory
      • Atrium Research
      • Baden Hill
      • BlytheRay
      • BNP Paribas Exane - Sponsored Research
      • Bondcritic
      • Brand Communications
      • BRR Media
      • Calvine Partners
      • Capital Access Group
      • Capital Link
      • Capital Markets Brokers
      • Cavendish
      • Checkpoint Partners
      • Clear Capital Markets
      • Couloir Capital
      • Doceo
      • Edison
      • Engage Investor
      • Equity Development
      • eResearch
      • First Equity
      • Five Minute Pitch TV
      • focusIR
      • Fundamental Research Corp
      • Galliano’s Latin Notes
      • GBC AG
      • goetzpartners securities Limited
      • Golden Section Capital
      • GreenSome Finance
      • GSBR Research
      • H2 Radnor
      • Hardman & Co
      • Holland Advisors
      • Hypothesis Research
      • InterAxS Global
      • Kepler | Trust Intelligence
      • London Stock Exchange
      • Longspur Clean Energy
      • Mello Events
      • Messari Research
      • Nippon Investment Bespoke Research UK
      • NuWays
      • OAK Securities
      • Oberon Capital
      • Optimo Capital
      • Panmure Liberum
      • Paul Scott
      • Peel Hunt
      • PIWORLD / Progressive
      • Proactive
      • Progressive Equity Research
      • Quantum Research Group
      • QuotedData
      • Research Dynamics
      • Research Tree
      • Resolve Research
      • SEAL Advisors Ltd
      • ShareSoc
      • Shore Capital
      • Sidoti & Company
      • Small Cap Consumer Research LLC
      • StockBox
      • Tennyson Securities
      • The AIC
      • The Business Magazine Group
      • The Edge Group
      • The Life Sciences Division
      • Trinity Delta
      • Turner Pope Investments
      • UK Investor Group
      • ValueTrack
      • Vox Markets
      • VRS International S.A. - Valuation & Research Specialists (VRS)
      • VSA Capital
      • Winterflood Securities
      • Yaru Investments
      • Yellowstone Advisory
      • Zacks Small Cap Research
      • Zeus Capital
    • High Net Worth Offering
      • Fox-Davies Capital
      • ABG Sundal Collier
      • ACF Equity Research
      • Align Research
      • Allenby Capital
      • AlphaValue
      • Alternative Resource Capital
      • Arctic Securities
      • Arden Partners
      • Auctus Advisors
      • Baptista Research
      • BNP Paribas Exane - Sponsored Research
      • Canaccord Genuity
      • Cavendish
      • Couloir Capital
      • Degroof Petercam
      • Dowgate Capital
      • First Berlin
      • First Equity
      • First Sentinel
      • Greenwood Capital Partners
      • Hannam & Partners
      • Hybridan
      • Kemeny Capital
      • Longspur Clean Energy
      • Louis Capital
      • Magnitogorsk Iron and steel works
      • Medley Global Advisors
      • Northland Capital Partners
      • OAK Securities
      • Oberon Capital
      • Panmure Liberum
      • QuotedData Professional
      • Shard Capital
      • ShareSoc
      • Shore Capital
      • Singer Capital Markets
      • SP Angel
      • Stanford Capital Partners
      • Stifel FirstEnergy
      • Stockdale Securities
      • Tamesis Partners
      • Tennyson Securities
      • The Life Sciences Division
      • Turner Pope Investments
      • VSA Capital
      • Whitman Howard
      • Yellowstone Advisory
      • Zeus Capital
    • Institutional Offering
      • Fox-Davies Capital
      • ABG Sundal Collier
      • ACF Equity Research
      • Acquisdata
      • Allenby Capital
      • Alternative Resource Capital
      • Arctic Securities
      • Arden Partners
      • Auctus Advisors
      • BNP Paribas Exane
      • Bondcritic
      • Canaccord Genuity
      • Capital Access Group
      • Capital Link
      • Cavendish
      • Couloir Capital
      • Degroof Petercam
      • Dowgate Capital
      • Edison
      • First Berlin
      • First Equity
      • First Sentinel
      • Five Minute Pitch TV
      • Fundamental Research Corp
      • Galliano’s Latin Notes
      • GBC AG
      • Golden Section Capital
      • Goodbody
      • Greenwood Capital Partners
      • Hannam & Partners
      • Holland Advisors
      • Hybridan
      • InterAxS Global
      • Investec Bank
      • Kepler | Trust Intelligence
      • Numis
      • NuWays
      • OAK Securities
      • Oberon Capital
      • Panmure Liberum
      • Peel Hunt
      • QuotedData
      • QuotedData Professional
      • Research Dynamics
      • Research Tree
      • Shard Capital
      • Shore Capital
      • Sidoti & Company
      • Singer Capital Markets
      • Small Cap Consumer Research LLC
      • SP Angel
      • Stanford Capital Partners
      • Stifel
      • StockBox
      • Tamesis Partners
      • Tennyson Securities
      • The AIC
      • The Business Magazine Group
      • The Life Sciences Division
      • ValueTrack
      • Velocity Trade
      • VSA Capital
      • Winterflood Securities
      • Zacks Small Cap Research
      • Zeus Capital
  • Contact
  • Sign Up
  • Sign In